deltatrials
Terminated PHASE2 INTERVENTIONAL 4-arm NCT03938545

ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )

ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy

Sponsor: Immunovant Sciences GmbH

Conditions Graves' Ophthalmopathy (GO)
Interventions Placebo (Administered via subcutaneous injection) RVT-1401 (Administered via subcutaneous injection)
Updated 16 times since 2019 Last updated: Aug 26, 2022 Started: Jul 23, 2019 Primary completion: Feb 2, 2021 Completion: Apr 15, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision based on premature unblinding of treatment allocations necessitated by program-wide review

Other terminated trials from Immunovant Sciences GmbH

More terminations from Immunovant Sciences GmbH

A PHASE2 clinical study on Graves' Ophthalmopathy (GO), this trial is terminated or withdrawn. The trial is conducted by Immunovant Sciences GmbH and has accumulated 16 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Mar 2020 · 2 months · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Sep 2022 · 9 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Sep 2022 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Dec 2021 — Sep 2022 [monthly]

    Terminated PHASE2

▶ Show 11 earlier versions

  1. Sep 2021 — Dec 2021 [monthly]

    Terminated PHASE2

    Status: Suspended → Terminated

  2. Mar 2021 — Sep 2021 [monthly]

    Suspended PHASE2

    Status: Recruiting → Suspended

  3. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  4. Mar 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Jan 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  6. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  7. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  8. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  9. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Jul 2019 — Aug 2019 [monthly]

    Not Yet Recruiting PHASE2

  11. Jun 2019 — Jul 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Immunovant Sciences GmbH
Data source: Immunovant Sciences GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Barcelona, Spain , Beverly Hills, United States , Duisburg, Germany , Frankfurt am Main, Germany , Houston, United States , Iowa City, United States , L'Hospitalet de Llobregat, Spain , Madrid, Spain , Mainz, Germany and 14 more locations